evidence table
Coenzyme Q10 Blood Pressure Randomized Trial Evidence Table
Structured evidence table for Coenzyme Q10 Blood Pressure Randomized Trial, generated from 1 reusable source document in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Coenzyme Q10 Blood Pressure Randomized Trial | Despite major advancements in pharmacotherapies and interventional cardiology, substantial residual risk persists among patients with established disease (). | 3 | Wu Xun (2026) | Advances in cardiovascular supplementation: mechanisms, efficacy, and clinical perspectives |
| Coenzyme Q10 Blood Pressure Randomized Trial | Additionally, many nutraceuticals are perceived to possess favorable safety and tolerability profiles compared to conventional medications, making them attractive for long-term risk reduction (). | 3 | Wu Xun (2026) | Advances in cardiovascular supplementation: mechanisms, efficacy, and clinical perspectives |
| Coenzyme Q10 Blood Pressure Randomized Trial | Banach et al., 2018 Cicero et al., 2017 Sesso et al., 2008 However, the field is marked by heterogeneous and sometimes contradictory evidence. | 3 | Wu Xun (2026) | Advances in cardiovascular supplementation: mechanisms, efficacy, and clinical perspectives |
| Coenzyme Q10 Blood Pressure Randomized Trial | Roth et al., 2020 Ganda et al., 2018 Visseren et al., 2021 Cardiovascular disease (CVD) is the leading cause of mortality worldwide, accounting for nearly one-third of global deaths each year (). | 3 | Wu Xun (2026) | Advances in cardiovascular supplementation: mechanisms, efficacy, and clinical perspectives |
Source documents